Denosumab for Giant Cell Tumors of Bone from 2010 to 2022: a Bibliometric Analysis

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2023 Apr 27

PMID 37103655

Authors

Xiaoqi Tan

Yue Zhang

Daiqing Wei

Yunkang Yang

Feifan Xiang

Affiliations

Soon will be listed here.

Abstract

Giant cell tumors of the bone (GCTB) are considered moderately malignant bone tumors. Denosumab, as a neoadjuvant therapy, provides new possibilities for treating GCTB. However, even after multiple studies and long-term clinical trials, there are limitations in the treatment process. Research data and Medical Subject Headings terms related to denosumab and GCTB were collected from January 2010 to October 2022 using the Web of Science and MeSH ( https://meshb.nlm.nih.gov ) browsers. These data were imported into CiteSpace and VOSviewer softwares for bibliometric analysis. Overall, 445 publications on denosumab and GCTB were identified. Over the last 12 years, the growth rate of the total number of publications has remained relatively stable. The USA published the highest number of articles (83) and had the highest centrality (0.42). Amgen Inc. and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) First Ortoped Rizzoli were identified as the most influential institutions. Many authors have made outstanding contributions to this field. Lancet Oncology had the highest journal impact factor (54.433). Local recurrence and drug dosage are current research hotspots, and future development trends will mainly focus on prognostic markers of GCTB and the development of new therapies. Further research is required to analyze denosumab's safety and efficacy and understand its local recurrence of GCTB, to identify the optimal dose. Future progress in this field will likely focus on exploring new diagnostic and recurrence markers to monitor disease progression and examine new therapeutic targets and treatment strategies.

Citing Articles

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?.

de la Calva C, Angulo M, Gonzalez-Rojo P, Peiro A, Machado P, Cebrian J Cancer Rep (Hoboken). 2025; 8(1):e70117.

PMID: 39797695 PMC: 11726647. DOI: 10.1002/cnr2.70117.

[One case of recurrent giant cell tumor of the larynx and literature review].

Liu Y, Xu K, Feng Q, Lu X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(11):1073-1076.

PMID: 39534902 PMC: 11879714. DOI: 10.13201/j.issn.2096-7993.2024.11.015.

Denosumab combined with microwave ablation excisional scraping for giant cell tumor of the thoracic spine: a case report and literature review.

Miao Z, Han Z, Zheng K, Xu M, Yu X, Han C Front Oncol. 2024; 14:1402550.

PMID: 39364313 PMC: 11446914. DOI: 10.3389/fonc.2024.1402550.

A bibliometric analysis based on hotspots and frontier trends of positron emission tomography/computed tomography utility in bone and soft tissue sarcoma.

Xiang F, Zhang Y, Tan X, Zhang J, Li T, Yan Y Front Oncol. 2024; 14:1344643.

PMID: 38974238 PMC: 11224451. DOI: 10.3389/fonc.2024.1344643.

Giant Cell Tumor of the Inferior Turbinate in a 12-Year-Old Child: First Case Report.

Linxweiler M, Remke M, Straub B, Schick B OTO Open. 2024; 8(2):e165.

PMID: 38938508 PMC: 11208738. DOI: 10.1002/oto2.165.

References

Choi J, Ro J . The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2020; 28(1):44-58. DOI: 10.1097/PAP.0000000000000284. View

Liede A, Bach B, Stryker S, Hernandez R, Sobocki P, Bennett B . Regional variation and challenges in estimating the incidence of giant cell tumor of bone. J Bone Joint Surg Am. 2014; 96(23):1999-2007. DOI: 10.2106/JBJS.N.00367. View

Chan C, Adler Z, Reith J, Gibbs Jr C . Risk factors for pulmonary metastases from giant cell tumor of bone. J Bone Joint Surg Am. 2015; 97(5):420-8. DOI: 10.2106/JBJS.N.00678. View

Sanjay B, Sim F, Unni K, Mcleod R, Klassen R . Giant-cell tumours of the spine. J Bone Joint Surg Br. 1993; 75(1):148-54. DOI: 10.1302/0301-620X.75B1.8421014. View

Goldring S, Roelke M, Petrison K, Bhan A . Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 1987; 79(2):483-91. PMC: 424109. DOI: 10.1172/JCI112838. View

Chen F, Wang S, Wei Y, Wu J, Huang G, Chen J . Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. Biomed Pharmacother. 2018; 103:1092-1100. DOI: 10.1016/j.biopha.2018.04.100. View

Ren B, Ren X, Wang L, Tu C, Zhang W, Liu Z . A bibliometric research based on hotspots and frontier trends of denosumab. Front Pharmacol. 2022; 13:929223. PMC: 9527327. DOI: 10.3389/fphar.2022.929223. View

Singh A, Chawla N, Chawla S . Giant-cell tumor of bone: treatment options and role of denosumab. Biologics. 2015; 9:69-74. PMC: 4507456. DOI: 10.2147/BTT.S57359. View

Synnestvedt M, Chen C, Holmes J . CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2006; :724-8. PMC: 1560567. View

10.

Chen C, Hu Z, Liu S, Tseng H . Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012; 12(5):593-608. DOI: 10.1517/14712598.2012.674507. View

11.

van Eck N, Waltman L . Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017; 111(2):1053-1070. PMC: 5400793. DOI: 10.1007/s11192-017-2300-7. View

12.

van Eck N, Waltman L . Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010; 84(2):523-538. PMC: 2883932. DOI: 10.1007/s11192-009-0146-3. View

13.

Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y . Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage. J Bone Joint Surg Am. 2018; 100(6):496-504. DOI: 10.2106/JBJS.17.00057. View

14.

Tsukamoto S, Mavrogenis A, Leone G, Righi A, Akahane M, Tanzi P . Denosumab does not decrease the risk of lung metastases from bone giant cell tumour. Int Orthop. 2018; 43(2):483-489. DOI: 10.1007/s00264-018-4085-6. View

15.

Lipplaa A, Dijkstra S, Gelderblom H . Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Curr Opin Oncol. 2019; 31(4):329-335. PMC: 6613724. DOI: 10.1097/CCO.0000000000000529. View

16.

Chawla S, Blay J, Rutkowski P, Cesne A, Reichardt P, Gelderblom H . Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019; 20(12):1719-1729. DOI: 10.1016/S1470-2045(19)30663-1. View

17.

Xu Y, Zhang Z, He J, Chen Z . Immune Effects of Macrophages in Rheumatoid Arthritis: A Bibliometric Analysis From 2000 to 2021. Front Immunol. 2022; 13:903771. PMC: 9510364. DOI: 10.3389/fimmu.2022.903771. View

18.

Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9. View

19.

Chawla S, Henshaw R, Seeger L, Choy E, Blay J, Ferrari S . Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013; 14(9):901-8. DOI: 10.1016/S1470-2045(13)70277-8. View

20.

Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J . Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010; 11(3):275-80. DOI: 10.1016/S1470-2045(10)70010-3. View